Yaacov R Lawrence1,2, Jennifer Moughan3, Anthony M Magliocco4, Alexander C Klimowicz5, William F Regine6, Rex B Mowat7, Thomas A DiPetrillo8, William Small9, Jeffry P Simko10, Talia Golan1, Kathryn A Winter3, Chandan Guha11, Christopher H Crane12, Adam P Dicker2. 1. Department of Oncology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel HaShomer, Israel. 2. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. 3. Statistics and Data Management Center, NRG Oncology, Philadelphia, Pennsylvania. 4. Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, Florida. 5. Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut. 6. University of Maryland School of Medicine, Baltimore, Maryland. 7. Toledo Clinic Cancer Centers, Toledo, Ohio. 8. Department of Radiation Oncology, Rhode Island Hospital/The Warren Alpert Medical School of Brown University, Providence, Rhode, Island. 9. Department of Radiation Oncology, Loyola University Medical Center, Chicago, Illinois. 10. Department of Pathology, University of California-San Francisco Medical Center, San Francisco, California. 11. Department of Radiation Oncology, Montefiore Medical Center, Bronx, New York. 12. Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: The majority of patients with pancreatic cancer who undergo curative resection experience rapid disease recurrence. In previous small studies, high expression of the mismatch-repair protein mutL protein homolog 1 (MLH1) in pancreatic cancers was associated with better outcomes. The objective of this study was to validate the association between MLH1 expression and survival in patients who underwent resection of pancreatic cancer and receivedadjuvant chemoradiation. METHODS: Samples were obtained from the NRG Oncology Radiation Therapy Oncology Group 9704 prospective, randomized trial (clinicaltrials.gov identifier NCT00003216), which compared 2 adjuvant protocols in patients with pancreatic cancer who underwent resection. Tissue microarrays were prepared from formalin-fixed, paraffin-embedded, resected tumor tissues. MLH1 expression was quantified using fluorescence immunohistochemistry and automated quantitative analysis, and expression was dichotomized above and below the median value. RESULTS:Immunohistochemical staining was successfully performed on 117 patients for MLH1 (60 and 57 patients from the 2 arms). The characteristics of the participants who had tissue samples available were similar to those of the trial population as a whole. At the time of analysis, 84% of participants had died, with a median survival of 17 months. Elevated MLH1 expression levels in tumor nuclei were significantly correlated with longer disease-free and overall survival in each arm individually and in both arms combined. Two-year overall survival was 16% in patients who had low MLH1 expression levels and 53% in those who had high MLH1 expression levels (P < .0001 for both arms combined). This association remained true on a multivariate analysis that allowed for lymph node status (hazard ratio, 0.41; 95% confidence interval, 0.27-0.63; P < .0001). CONCLUSIONS: In the current sample, MLH1 expression was correlated with long-term survival. Further studies should assess whether MLH1 expression predicts which patients with localized pancreatic cancer may benefit most from aggressive, multimodality treatment. Cancer 2018;124:491-8.
RCT Entities:
BACKGROUND: The majority of patients with pancreatic cancer who undergo curative resection experience rapid disease recurrence. In previous small studies, high expression of the mismatch-repair protein mutL protein homolog 1 (MLH1) in pancreatic cancers was associated with better outcomes. The objective of this study was to validate the association between MLH1 expression and survival in patients who underwent resection of pancreatic cancer and received adjuvant chemoradiation. METHODS: Samples were obtained from the NRG Oncology Radiation Therapy Oncology Group 9704 prospective, randomized trial (clinicaltrials.gov identifier NCT00003216), which compared 2 adjuvant protocols in patients with pancreatic cancer who underwent resection. Tissue microarrays were prepared from formalin-fixed, paraffin-embedded, resected tumor tissues. MLH1 expression was quantified using fluorescence immunohistochemistry and automated quantitative analysis, and expression was dichotomized above and below the median value. RESULTS: Immunohistochemical staining was successfully performed on 117 patients for MLH1 (60 and 57 patients from the 2 arms). The characteristics of the participants who had tissue samples available were similar to those of the trial population as a whole. At the time of analysis, 84% of participants had died, with a median survival of 17 months. Elevated MLH1 expression levels in tumor nuclei were significantly correlated with longer disease-free and overall survival in each arm individually and in both arms combined. Two-year overall survival was 16% in patients who had low MLH1 expression levels and 53% in those who had high MLH1 expression levels (P < .0001 for both arms combined). This association remained true on a multivariate analysis that allowed for lymph node status (hazard ratio, 0.41; 95% confidence interval, 0.27-0.63; P < .0001). CONCLUSIONS: In the current sample, MLH1 expression was correlated with long-term survival. Further studies should assess whether MLH1 expression predicts which patients with localized pancreatic cancer may benefit most from aggressive, multimodality treatment. Cancer 2018;124:491-8.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Ann Surg Oncol Date: 2011-03-10 Impact factor: 5.344
Authors: José L McFaline-Figueroa; Christian J Braun; Monica Stanciu; Zachary D Nagel; Patrizia Mazzucato; Dewakar Sangaraju; Edvinas Cerniauskas; Kelly Barford; Amanda Vargas; Yimin Chen; Natalia Tretyakova; Jacqueline A Lees; Michael T Hemann; Forest M White; Leona D Samson Journal: Cancer Res Date: 2015-05-29 Impact factor: 12.701
Authors: Luigi Laghi; Stefania Beghelli; Antonino Spinelli; Paolo Bianchi; Gianluca Basso; Giuseppe Di Caro; Anna Brecht; Giuseppe Celesti; Giona Turri; Samantha Bersani; Guido Schumacher; Christoph Röcken; Ilona Gräntzdörffer; Massimo Roncalli; Alessandro Zerbi; Peter Neuhaus; Claudio Bassi; Marco Montorsi; Aldo Scarpa; Alberto Malesci Journal: PLoS One Date: 2012-09-21 Impact factor: 3.240
Authors: C Ghimenti; P Tannergård; S Wahlberg; T Liu; P G Giulianotti; F Mosca; G Fornaciari; G Bevilacqua; A Lindblom; M A Caligo Journal: Br J Cancer Date: 1999-04 Impact factor: 7.640
Authors: Nikhil Yegya-Raman; Mihir M Shah; Miral S Grandhi; Elizabeth Poplin; David A August; Timothy J Kennedy; Usha Malhotra; Kristen R Spencer; Darren R Carpizo; Salma K Jabbour Journal: Ann Pancreat Cancer Date: 2018-08-06
Authors: Lei Huang; Yesilda Balavarca; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Vesna Zadnik; Maja Primic-Žakelj; Margit Mägi; Robert Grützmann; Marc G Besselink; Petra Schrotz-King; Hermann Brenner; Lina Jansen Journal: BMC Med Date: 2019-03-25 Impact factor: 8.775